Review of recent studies on interventions for cognitive deficits in patients with cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 2, 2012, Pages 255-269

  Gehring, Karin ^a   Roukema, Jan Anne ^a   Sitskoorn, Margriet M ^a  

^a TILBURG UNIVERSITY   (Netherlands)

Author keywords

cancer; central nervous system stimulants; chemotherapy; cognition disorders; neuroprotective agents; rehabilitation; therapeutics

Indexed keywords

DEXMETHYLPHENIDATE; ESTRADIOL; ESTROGEN; GINKGO BILOBA EXTRACT; IBUPROFEN; MELATONIN; METHYLPHENIDATE; MODAFINIL; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL CRAMP; AEROBIC EXERCISE; ANEMIA; ANXIETY DISORDER; ARTHRALGIA; ATTENTION DEFICIT DISORDER; BACKACHE; BLOATING; BONE PAIN; CANCER PATIENT; COGNITION; COGNITIVE DEFECT; COGNITIVE REHABILITATION; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; FATIGUE; HAIR LOSS; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPOGONADISM; HYPOKALEMIA; INSOMNIA; IRRITABILITY; KINESIOTHERAPY; LEUKOPENIA; MAJOR DEPRESSION; MASTALGIA; MYALGIA; NARCOLEPSY; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PAIN; QUALITY OF LIFE; RASH; REVIEW; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; STOMATITIS; SYSTEMATIC REVIEW; THORAX PAIN; THROMBOSIS; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; HORMONE REPLACEMENT THERAPY; HUMANS; NEOPLASMS;

EID: 84856847558     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.202     Document Type: Review

References (90)

1. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 13(12), 1285-1295 (2008). .. Provides a clear overview of the cranial imaging abnormalities and biological cell mechanisms of chemotherapy- and radiotherapy-related toxicities, and their consequences for cognitive function.
2. Froklage FE, Reijneveld JC, Heimans JJ. Central neurotoxicity in cancer chemotherapy: Pharmacogenetic insights. Pharmacogenomics 12(3), 379-395 (2011). .. Explains clearly the candidate genetic mechanisms that are involved in the CNS toxicities, including cognitive function, that are associated with chemotherapy.
3. de Ruiter MB, Reneman L, Boogerd W et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum. Brain Mapp. 32(8), 1206-1219 (2011).
4. Raffa RB. Imaging as a means of studying chemotherapy-related cognitive impairment. Adv. Exp. Med. Biol. 678, 70-76 (2010).
5. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Gray matter reduction associated with systemic chemotherapy for breast cancer: A prospective MRI study. Breast Cancer Res. Treat. 123(3), 819-828 (2010).
6. Silverman DH, Dy CJ, Castellon SA et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res. Treat. 103(3), 303-311 (2007). (Pubitemid 46944511)
7. Inagaki M, Yoshikawa E, Matsuoka Y et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109(1), 146-156 (2007). (Pubitemid 46120202)
8. Schneiderman B. Hippocampal volumes smaller in chemotherapy patients. Lancet Oncol. 5(4), 202 (2004). (Pubitemid 38391208)
9. Marsh JC, Gielda BT, Herskovic AM, Abrams RA. Cognitive sparing during the administration of whole brain radiotherapy and prophylactic cranial irradiation: Current concepts and approaches. J. Oncol. 2010, 198208 (2010).
10. Deckert M, Engert A, Bruck W et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia doi:10.1038/leu.2011.169 (2011) (Epub ahead of print).
11. Dickinson MD, Barr CD, Hiscock M, Meyers CA. Cognitive effects of pegylated interferon in individuals with primary brain tumors. J. Neurooncol. 95(2), 231-237 (2009).
12. Scheibel RS, Valentine AD, O'Brien S, Meyers CA. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J. Neuropsychiatry Clin. Neurosci. 16(2), 185-191 (2004). (Pubitemid 38560902)
13. Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol. Rev. 18(2), 121-131 (2008).
14. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: A review. Cancer 113(5), 1097-1106 (2008).
15. Alibhai SM, Breunis H, Timilshina N et al. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J. Clin. Oncol. 28(34), 5030-5037 (2010).
16. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85(3), 640-650 (1999). (Pubitemid 29075285)
17. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12(7), 703-708 (2011).
18. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: A prologue. Cancer 101(3), 466-475 (2004).
19. Hermelink K, Untch M, Lux MP et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study. Cancer 109(9), 1905-1913 (2007). (Pubitemid 46668557)
20. Ahles TA, Saykin AJ, McDonald BC et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res. Treat. 110(1), 143-152 (2008). (Pubitemid 351793851)
21. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS. Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. J. Natl Cancer Inst. 98(23), 1742-1745 (2006). (Pubitemid 44942713)
22. Hurria A, Rosen C, Hudis C et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. J. Am. Geriatr. Soc. 54(6), 925-931 (2006). (Pubitemid 43847029)
23. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104(4), 788-793 (2005). (Pubitemid 41113679)
24. Meyers CA, Byrne KS, Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 12(3), 231-235 (1995).
25. Gehring K, Sitskoorn MM, Aaronson NK, Taphoorn MJ. Interventions for cognitive deficits in adults with brain tumours. Lancet Neurol. 7(6), 548-560 (2008). . Includes an overview of previously conducted studies examining prevention and treatment of cognitive deficits in patients with cancers outside the CNS. (Pubitemid 351657495)
26. Gehring K, Aaronson NK, Taphoorn MJ, Sitskoorn MM. Interventions for cognitive deficits in patients with a brain tumor: An update. Expert Rev. Anticancer Ther. 10(11), 1779-1795 (2010).
27. Fernandez F, Adams F. Methylphenidate treatment of patients with head and neck cancer. Head Neck Surg. 8(4), 296-300 (1986).
28. Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: A prospective clinical study. J. Psychiatry Neurosci. 30(2), 100-107 (2005).
29. Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 48(2), 163-166 (1992).
30. Mar Fan HG, Clemons M, Xu W et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support. Care Cancer 16(6), 577-583 (2008).
31. Massa E, Madeddu C, Lusso MR, Gramignano G, Mantovani G. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit. Rev. Oncol. Hematol. 57(2), 175-182 (2006). (Pubitemid 43139702)
32. O'Shaughnessy JA, Vukelja SJ, Holmes FA et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin. Breast Cancer 5(6), 439-446 (2005).
33. Capuron L, Gumnick JF, Musselman DL et al. Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26(5), 643-652 (2002). (Pubitemid 34260983)
34. Chan AS, Cheung MC, Law SC, Chan JH. Phase II study of alpha-tocopherol in improving the cognitive function of patients with temporal lobe radionecrosis. Cancer 100(2), 398-404 (2004). (Pubitemid 38063651)
35. Jatoi A, Kahanic SP, Frytak S et al. Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: Preliminary results and suggestions for future study designs. Support. Care Cancer 13(1), 66-69 (2005). (Pubitemid 40193067)
36. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest. 13(6), 561-566 (1995).
37. Berridge CW, Devilbiss DM. Psychostimulants as cognitive enhancers: The prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder. Biol. Psychiatry 69(12), e101-e111 (2011).
38. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: Insights from PET imaging studies. J. Atten. Disord. 6(Suppl. 1), S31-S43 (2002).
39. Hannestad J, Gallezot JD, Planeta-Wilson B et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol. Psychiatry 68(9), 854-860 (2010).
40. Butler JM Jr, Case LD, Atkins J et al. A Phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo- methylphenidate HCl in brain tumor patients receiving radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 69(5), 1496-1501 (2007). (Pubitemid 350116415)
41. Lower EE, Fleishman S, Cooper A et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: A randomized clinical trial. J. Pain Symptom Manage. 38(5), 650-662 (2009).
42. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: A pilot study of exercise and methylphenidate. Oncol. Nurs. Forum 29(7), E85-E90 (2002).
43. Volkow ND, Fowler JS, Logan J et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications. JAMA 301(11), 1148-1154 (2009).
44. Young JW, Geyer MA. Action of modafinil - increased motivation via the dopamine transporter inhibition and D1 receptors? Biol. Psychiatry 67(8), 784-787 (2010).
45. Minzenberg MJ, Watrous AJ, Yoon JH, Ursu S, Carter CS. Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI. Science 322(5908), 1700-1702 (2008).
46. Lundorff LE, Jonsson BH, Sjogren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: A double-blind, randomised, cross-over trial. Palliat. Med. 23(8), 731-738 (2009).
47. Blackhall L, Petroni G, Shu J, Baum L, Farace E. A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J. Palliat. Med. 12(5), 433-439 (2009).
48. Kohli S, Fisher SG, Tra Y et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115(12), 2605-2616 (2009).
49. Schaller BJ, Buchfelder M. Neuroprotection in primary brain tumors: Sense or nonsense? Expert Rev. Neurother. 6(5), 723-730 (2006). (Pubitemid 43961876)
50. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 6(6), 484-494 (2005). (Pubitemid 40769173)
51. Fan HG, Park A, Xu W et al. The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 18(2), 156-161 (2009).
52. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J. Clin. Oncol. 23(12), 2597-2605 (2005). (Pubitemid 46179448)
53. Iconomou G, Koutras A, Karaivazoglou K et al. Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. Eur. J. Cancer Care (Engl.) 17(6), 535-541 (2008).
54. Taxel P, Stevens MC, Trahiotis M, Zimmerman J, Kaplan RF. The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer. J. Am. Geriatr. Soc. 52(2), 269-273 (2004). (Pubitemid 38233492)
55. Matousek RH, Sherwin BB. A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog. Psychoneuroendocrinology 35(2), 215-225 (2010).
56. Beer TM, Bland LB, Bussiere JR et al. Testosterone loss and estradiol administration modify memory in men. J. Urol. 175(1), 130-135 (2006). (Pubitemid 41797110)
57. Sharma P, Wisniewski A, Braga-Basaria M et al. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J. Urol. 182(5), 2265-2272 (2009).
58. Poppelreuter M, Weis J, Mumm A, Orth HB, Bartsch HH. Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 41(1), 79-90 (2008).
59. McDougall GJ Jr. Memory improvement program for elderly cancer survivors. Geriatr. Nurs. 22(4), 185-190 (2001).
60. Cimprich B. Development of an intervention to restore attention in cancer patients. Cancer Nurs. 16(2), 83-92 (1993). (Pubitemid 23119156)
61. Cimprich B, Ronis DL. An environmental intervention to restore attention in women with newly diagnosed breast cancer. Cancer Nurs. 26(4), 284-292 (2003). (Pubitemid 36903882)
62. Poppelreuter M, Weis J, Bartsch HH. Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J. Psychosoc. Oncol. 27(2), 274-296 (2009).
63. McDougall GJ, Becker H, Acee TW, Vaughan PW, Delville CL. Symptom management of affective and cognitive disturbance with a group of cancer survivors. Arch. Psychiatr. Nurs. 25(1), 24-35 (2011).
64. Ferguson RJ, Ahles TA, Saykin AJ et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 16(8), 772-777 (2007). (Pubitemid 47249179)
65. Ferguson RJ, McDonald BC, Rocque MA et al. Development of CBT for chemotherapy-related cognitive change: Results of a waitlist control trial. Psychooncology doi:10.1002/pon.1878 (2010) (Epub ahead of print).
66. Mar Fan HG, Clemons M, Xu W et al. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support. Care Cancer 16(6), 577-583 (2008).
67. Meyers CA, Wefel JS. The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials: No ifs, ands, buts, or sensitivity. J. Clin. Oncol. 21(19), 3557-3558 (2003). (Pubitemid 46594045)
68. Buemi M, Caccamo C, Nostro L, Cavallaro E, Floccari F, Grasso G. Brain and cancer: The protective role of erythropoietin. Med. Res. Rev. 25(2), 245-259 (2005). (Pubitemid 40305278)
69. Schilder CM, Seynaeve C, Beex LV et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: Results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J. Clin. Oncol. 28(8), 1294-1300 (2010).
70. Gehring K, Sitskoorn MM, Gundy CM et al. Cognitive rehabilitation in patients with gliomas: A randomized, controlled trial. J. Clin. Oncol. 27(22), 3712-3722 (2009).
71. Wilson BA. Long-term prognosis of patients with severe memory disorders. Neuropsychol. Rehabil. 1(2), 117-134 (1991).
72. Berg IJ, Koning-Haanstra M, Deelman BG. Long-term effects of memory rehabilitation: A controlled study. Neuropsychol. Rehabil. 1(2), 97-111 (1991).
73. Gray JM, Robertson I, Pentland B, Anderson S. Microcomputer-based attentional retraining after brain damage: A randomised group controlled trial. Neuropsychol. Rehabil. 2(2), 97-115 (1992).
74. Winkens I, Van Heugten CM, Wade DT, Habets EJ, Fasotti L. Efficacy of time pressure management in stroke patients with slowed information processing: A randomized controlled trial. Arch. Phys. Med. Rehabil. 90(10), 1672-1679 (2009).
75. Sawrie SM, Martin R, Kuzniecky R et al. Subjective versus objective memory change after temporal lobe epilepsy surgery. Neurology 53(7), 1511-1517 (1999). (Pubitemid 29491946)
76. Cull A, Hay C, Love SB, Mackie M, Smets E, Stewart M. What do cancer patients mean when they complain of concentration and memory problems? Br. J. Cancer 74(10), 1674-1679 (1996). (Pubitemid 26386101)
77. Schagen SB, Boogerd W, Muller MJ et al. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol. 47(1), 63-70 (2008).
78. Klein M, Reijneveld JC, Heimans JJ. Subjective ratings vs. objective measurement of cognitive function: In regard to Van Beek et al. (Int. J. Radiat. Oncol. Biol. Phys. 68, 986-991 [2007]). Int. J. Radiat. Oncol. Biol. Phys. 70(3), 961-962 (2008). (Pubitemid 351199718)
79. Middleton LS, Denney DR, Lynch SG, Parmenter B. The relationship between perceived and objective cognitive functioning in multiple sclerosis. Arch. Clin. Neuropsychol. 21(5), 487-494 (2006). (Pubitemid 44247524)
80. Hall KE, Isaac CL, Harris P. Memory complaints in epilepsy: An accurate reflection of memory impairment or an indicator of poor adjustment? A review of the literature. Clin. Psychol. Rev. 29(4), 354-367 (2009).
81. Chaytor N, Schmitter-Edgecombe M. The ecological validity of neuropsychological tests: A review of the literature on everyday cognitive skills. Neuropsychol. Rev. 13(4), 181-197 (2003). . Interesting theoretical discussion of the ecological validity of neuropsychological tests and comprehensive review of the research on this subject.
82. Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise training on elderly persons with cognitive impairment and dementia: A meta-analysis. Arch. Phys. Med. Rehabil. 85(10), 1694-1704 (2004). (Pubitemid 39349417)
83. Angevaren M, Aufdemkampe G, Verhaar HJ, Aleman A, Vanhees L. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst. Rev. 3, CD005381 (2008).
84. van Uffelen JG, Chin APMJ, Hopman-Rock M, van Mechelen W. The effects of exercise on cognition in older adults with and without cognitive decline: A systematic review. Clin. J. Sport Med. 18(6), 486-500 (2008).
85. Kramer AF, Erickson KI. Capitalizing on cortical plasticity: Influence of physical activity on cognition and brain function. Trends Cogn. Sci. 11(8), 342-348 (2007). . Overview of epidemiological or prospective observational studies, randomized human clinical interventions and nonhuman animal studies that support the claim that physical activity enhances cognitive and brain function, and protects against the development of neurodegenerative diseases. (Pubitemid 47077916)
86. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst. Rev. 2, CD006145 (2008).
87. Knols R, Aaronson NK, Uebelhart D, Fransen J, Aufdemkampe G. Physical exercise in cancer patients during and after medical treatment: A systematic review of randomized and controlled clinical trials. J. Clin. Oncol. 23(16), 3830-3842 (2005).
88. Courneya KS, Sellar CM, Stevinson C et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J. Clin. Oncol. 27(27), 4605-4612 (2009).
89. Seigers R, Fardell JE. Neurobiological basis of chemotherapy-induced cognitive impairment: A review of rodent research. Neurosci. Biobehav. Rev. 35(3), 729-741 (2011). .. Well-written, critical overview of the candidate mechanisms of chemotherapy-related cognitive impairment, and potential interventions that target these mechanisms, as evidenced in rodent research.
90. Oh B, Butow PN, Mullan BA et al. Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: A randomized controlled trial. Support. Care Cancer doi:10.1007/s00520-011-1209-6 (2011) (Epub ahead of print).